We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$269M
1-Year Est. Return
103.38%
This Fund
S&P 500
This Quarter
Est. Return
+22.87%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$269M
AUM Growth
+$20.3M
(+8.2%)
Cap. Flow
-$13.3M
Cap. Flow
% of AUM
-4.93%
Top 10 Holdings %
Top 10 Hldgs %
74.04%
Holding
45
New
9
Increased
7
Reduced
11
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verastem
VSTM
|
+$8.94M |
| 2 |
ABVX
Abivax
ABVX
|
+$2.36M |
| 3 |
Fennec Pharmaceuticals
FENC
|
+$2.28M |
| 4 |
HELP
Cybin Inc
HELP
|
+$2.13M |
| 5 |
Neuraxis
NRXS
|
+$1.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$6.54M |
| 2 |
Viridian Therapeutics
VRDN
|
+$4.9M |
| 3 |
Vaxcyte
PCVX
|
+$4.89M |
| 4 |
Celldex Therapeutics
CLDX
|
+$4.2M |
| 5 |
DFTX
Definium Therapeutics
DFTX
|
+$2.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.9% |
| 2 | Miscellaneous | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Kura Oncology
KURA
$1.01B
| $1.1M | 0.41% |
100,000
| – | – |
|
|
SPRB
27
Spruce Biosciences
SPRB
$159M
| $1.08M | 0.4% |
+20,000
| New | +$1.12M |
|
28
Aquestive Therapeutics
AQST
$604M
| $1.04M | 0.39% |
250,000
| – | – |
|
|
OKUR
29
OnKure Therapeutics
OKUR
$119M
| $684K | 0.25% |
150,000
-293,763
| -66% | -$1.26M |
|
30
PepGen
PEPG
$200M
| $630K | 0.23% |
+350,000
| New | +$569K |
|
|
31
CALL
CG Oncology
CGON
$6.43B
| $375K | 0.14% |
+31,000
| New | +$2.03M |
|
32
CALL
EyePoint Inc
EYPT
$316M
| $131K | 0.05% |
+50,300
| New | +$673K |
|
33
PUT
iShares S&P 100 ETF
OEF
$20.1B
| $110K | 0.04% |
+500,000
| New | +$179M |
|
34
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.87B
| $35.1K | 0.01% |
+140,600
| New | +$47M |
|
35
PUT
Tenax Therapeutics
TENX
$68.5M
| $13.9K | 0.01% |
+6,200
| New | +$79.2K |
|
36
Annexon
ANNX
$743M
| – | – |
-200,000
| Closed | -$1.11M |
|
37
Avalo Therapeutics
AVTX
$862M
| – | – |
-75,000
| Closed | -$1.12M |
|
|
38
CG Oncology
CGON
$6.43B
| – | – |
-100,000
| Closed | -$6.54M |
|
39
Lipocine
LPCN
$18.1M
| – | – |
-221,616
| Closed | -$1.77M |
|
|
DFTX
40
Definium Therapeutics
DFTX
$4.95B
| – | – |
-125,000
| Closed | -$2.36M |
|
41
PUT
Invesco QQQ Trust
QQQ
$474B
| – | – |
-250,000
| Closed | -$1.05M |
|
42
CALL
Replimune Group
REPL
$1.23B
| – | – |
-1,275,600
| Closed | -$2.75M |
|
43
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$799B
| – | – |
-125,000
| Closed | -$959K |
|
|
44
Viridian Therapeutics
VRDN
$2.47B
| – | – |
-250,401
| Closed | -$4.9M |
|
|
45
PUT
Viridian Therapeutics
VRDN
$2.47B
| – | – |
-263,600
| Closed | -$52.7K |
|
Similar funds
GPFA
AFO
TW
PM
ZEP
LBW
VP
5W
Rosalind Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Rosalind Advisors held 45 positions worth $269M, up 8.2% from $249M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Rosalind Advisors withdrew a net $13.3M in Q2 2026, closing 10 positions and reducing 11 holdings. Its most notable exit was CG Oncology, an estimated $6.54M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, Rosalind Advisors opened a new position in Abivax worth $2.78M.
- Rosalind Advisors's largest Q2 2026 buy was Abivax: 20,869 shares worth $2.78M.
- Rosalind Advisors added most to Verastem in Q2 2026, an estimated $8.94M increase.
- Rosalind Advisors's biggest Q2 2026 reduction was Vaxcyte, cutting an estimated $4.89M.
- Rosalind Advisors fully exited CG Oncology in Q2 2026, selling an estimated $6.54M.
- Rosalind Advisors's ten largest holdings make up 74% of its $269M portfolio in Q2 2026.
- Rosalind Advisors opened 9 new positions and closed 10 in Q2 2026.
- Rosalind Advisors's portfolio value rose 8.2% quarter-over-quarter to $269M.
Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.